

H1500.H15B Lot No. 886

Cryopreserved Human Hepatocytes

Donor Information

 Demographics
 Serology

 Gender:
 Female
 CMV: (+)

 Age:
 28 Years
 HIV: (-)

 Race:
 African American
 HBV: (-)

 Cause of Death:
 Head Trauma
 HCV: (-)

Assured Minimum Yield: 4.0×10^6 per vial

Viability: 86.6%

(Yield and viability are based on experiments performed at XenoTech using XenoTech's thawing protocol and Hepatocyte Isolation Kit.)

Enzyme	Marker substrate reaction (pmol/cells per inc/min)
CYP1A2	Phenacetin O-dealkylation	39.3 ± 1.1
CYP2A6	Coumarin 7-hydroxylation	52.9 ± 5.9
CYP2B6	Bupropion hydroxylation	13.8 ± 1.5
CYP2C8	Amodiaquine N-dealkylation	100 ± 8
CYP2C9	Diclofenac 4'-hydroxylation	339 ± 57
CYP2C19	S-Mephenytoin 4'-hydroxylation	13.3 ± 1.2
CYP2D6	Dextromethorphan O-demethylation	56.1 ± 4.0
CYP2E1	Chlorzoxazone 6-hydroxylation	155 ± 33
CYP3A4/5	Testosterone 6β-hydroxylation	405 ± 18
CYP3A4/5	Midazolam 1'-hydroxylation	89.0 ± 15.0
CYP4A11	Lauric acid 12-hydroxylation	TBD

CAUTION: These hepatocyte samples are from donors who tested negative for HIV and hepatitis. However, we recommend that these samples be considered as potential biohazards and that universal precautions be used when working with human derived products.

Store vials in liquid nitrogen, vapor phase.



Data sheet prepared 12/8/08